UniCAR-T-CD123
Phase 1- Indications
- Hematological malignancies
Company intelligence / Profile preview
Cellex has developed over 50 pioneering diagnostic tests across multiple platforms. During the COVID‑19 pandemic, it rapidly brought several commercial tests to market. Its SUSPENCE® bioreactor technology claims up to 10x higher cellular production efficiency than competitors and significant cost reductions in vaccine manufacturing simulations[5][1].
3 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cellex Incorporated.